Skip to content

Compounds · Metabolic & weight · Treatment of obesity and type 2 diabetes

Mazdutide (LY3305677 / IBI362)

Full protocol

LY3305677, IBI362, OXM3

Dual GLP-1/glucagon receptor agonist (LY3305677/IBI362) discovered in 2018, combining GLP-1 and glucagon signaling for stronger metabolic effects than single-receptor drugs. In Phase 3 trials for obesity and type 2 diabetes, showing notable weight loss and glycemic improvement.

1.5 → 6 mg weekly, titrated

Research score 85/100. Reference only, not a prescription.

  • Appetite Suppression
  • Metabolic Enhancement
  • Blood Sugar Control
  • GLP-1 Agonist
  • Weight Loss
  • Insulin Regulation
US status
Investigational
Approval
Phase 3 Clinical Trial
Evidence
Investigational GLP-1R and GCGR dual agonist. Shows significant weight loss and glycemic control in Type 2 diabetes and obesity trials.
Research score
85 / 100
Indication
Obesity/Weight Management
Origin
China
Source category
Digestive System
Status group
Investigational

Mechanism

GLP-1 receptor activation boosts glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and promotes satiety, while glucagon receptor activation raises energy expenditure and lipid metabolism; structural changes resist DPP-4 breakdown and bind albumin for once-weekly dosing.

Safety file

Mostly mild-to-moderate GI effects (nausea, diarrhea, vomiting), transient; some increased heart rate; low rate of serious adverse events, with no severe hypoglycemia in non-diabetics.

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Injection site reactions
  • Headache

Reconstitution

Concentration by vial size and water volume
Vial1 mL water2 mL water
10 mg10 mg/mL5 mg/mL
  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard titration (once weekly, subcutaneous)

  • Weeks 1 to 4: 1.5 mg
  • Weeks 5 to 8: 3 mg
  • Weeks 9 to 12: 4.5 mg
  • Week 13 onward: 6 mg as the maintenance dose
  • (A simpler 2 mg, then 4 mg, then 6 mg version on the same 4-week steps is also used.)

Dosing detail

  • Start at 1.5 mg and step up every 4 weeks. Going too fast is the top reason people quit, almost always from nausea.
  • Maintenance is commonly 6 mg weekly. China approved it at 4 mg and 6 mg in 2025 (brand name Xinermei), and a higher 9 mg dose (titrated 3, 6, 9) is under review there for severe obesity.
  • Some step down to 4.5 mg or 3 mg once at goal to hold results with fewer side effects.
  • One consistent day per week.

Duration

  • Titrate over 12 to 16 weeks, then maintain. Like the other GLP-1 class drugs, stopping tends to bring weight back.

Notes

  • A GLP-1 / glucagon dual agonist, so appetite suppression plus a metabolic bump are the headline effects.
  • Inject subcutaneously and rotate sites.
  • GI effects are dose-related and ease with slow titration.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard